Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Tuesday, May 12, 2009

Antimicrobial Protein Produced by Vaginal Lactobacillus acidophilus that inhibits Gardnerella vaginalis

Alla A. Aroutcheva, Jose A. Simoes, and Sebastian Faro
Department of Obstetrics and Gynecology, Rush-Presbyterian-St. Luke's Medical Center, 1653W. Congress Pkwy, 720 Pav., Chicago, IL, 60612, USA,
Infect Dis Obstet Gynecol 2001;9:33–39

Objective: The objective of this study was to develop a simple method for recovery and purification of the antimicrobial protein produced by endogenous vaginal L. acidophilus. Obtaining a pure bacteriocin will permit investigations leading to a better understanding of the interaction between the endogenous bacteria of the vagina..

All nine isolates of Gardnerella were inhibited by the bacteriocin isolated from L. acidophilus 160.
Methods: L. acidophilus 160 was grown on two media. The first was MRS broth for 18 hours; the cells were harvested, washed, and placed into a chemically defined medium. The second medium resembled vaginal fluid minus protein. Bacteriocin was precipitated from both media using ammonium sulfate. The growth-inhibiting activity of bacteriocin was determined by a bioassay using nine different isolates of Gardnerella vaginalis.

Results: MRS broth is not a suitable medium for extracting bacteriocin, because it binds with Tween 80. Bacteriocin was isolated, without contaminating constituents, from chemically defined medium and identified as a single band by electrophoresis. Bacteriocin has a molecular weight of 3.8 kDa. All nine isolates of Gardnerella were inhibited by the bacteriocin isolated from L. acidophilus 160.

Lactobacilli, through the antagonistic interaction
with pathogenic bacteria, maintain the vaginal ecosystem in a healthy state.
Conclusions: Bacteriocin produced by L. acidophilus 160 was isolated from the chemically defined medium (starvation medium) in a partially pure form. L. acidophilus 160 bacteriocin inhibited growth of all nine isolates of Gardnerella vaginalis

Lactobacilli, through the antagonistic interaction with pathogenic bacteria, maintain the vaginal ecosystem in a healthy state. Regulatory processes are carried out by species of Lactobacillus that produce antibacterial compounds, such as lactic and other organic acids, H2O2, and bacteriocins. Bacteriocins are biologically active, lowmolecular-weight proteins or peptides that inhibit the growth of a variety of bacteria.

The bacteriocin activity includes other species of lactobacilli, as well as a variety of Gram-positive and Gram-negative aerobic, facultative, and obligate anaerobic bacteria. It is significant that one species of Lactobacillus will produce a bacteriocin that inhibits the growth of other lactobacilli. This may be one mechanism that allows Lactobacillus to dominate the ecosystem by suppressing not only other bacteria but also other lactobacilli. This in turn reduces competition within an ecosystem.


Full text:

Related Posts:

Part 2 of interview with Cass Nelson-Dooley of Metametrix [keyword: lactobacillus]

Probiotics - Lactobacillus acidophilus


Post a Comment